SCHEMBL6410982

SCHEMBL6410982

CC(=O)N(C)Cc1cccc(C(F)(F)F)c1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 1/20 0.56
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
MAOB P27338 2/20 0.50
TACR1 P25103 2/20 0.50
ACP3 P15309 1/20 0.50
PDK2 Q15119 1/20 0.50
PDK1 Q15118 1/20 0.48
CETP P11597 2/20 0.48
OPRM1 P35372 1/20 0.48
OPRL1 P41146 1/20 0.48
MTOR P42345 1/20 0.48
EPHX1 P07099 1/20 0.48
HTR2A P28223 1/20 0.47
HTR2C P28335 1/20 0.47
HTR2B P41595 1/20 0.47
ALDH1A1 P00352 2/20 0.47
KDM4E B2RXH2 1/20 0.47
GFER P55789 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29565828 0.85 TACR1 (0.53) HDAC6MEN1KMT2ATACR1ACP3
SCHEMBL21392795 0.84 TACR1 (0.52) HDAC6MEN1KMT2ATACR1ACP3
SCHEMBL10547820 0.81 PDK1 (0.47) HDAC6MEN1KMT2AMAOBTACR1
SCHEMBL3878422 0.80 TACR1 (0.53) HDAC6MEN1KMT2AMAOBTACR1
SCHEMBL4243270 0.80 HTR2A (0.56) HDAC6MEN1KMT2AACP3CETP
SCHEMBL6415244 0.79 MEN1 (0.47) HDAC6MEN1KMT2ATACR1ACP3
SCHEMBL6415243 0.79 MEN1 (0.47) HDAC6MEN1KMT2ATACR1ACP3
SCHEMBL6417274 0.79 RIPK1 (0.64) MEN1KMT2AMAOBPDK2ALDH1A1
Hydrochloric Acid SCHEMBL8390076 0.78 IDO1 (0.54) MEN1KMT2AMAOBACP3CETP
SCHEMBL29693639 0.78 EPHX1 (0.51) HDAC6MEN1KMT2AMAOBACP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116327950-A Use of a composition for the treatment of neuropsychiatric symptoms of neurodegenerative diseases 阿泽范药品公司 2023-06-27 CN disclosed
CN-116139282-A Compositions and methods for treating neurodegenerative diseases 阿泽范药品公司 2023-05-23 CN disclosed
US-20050043370-A1 HIV integrase inhibitors WALKER MICHAEL A (US) 2005-02-24 US disclosed
US-6803378-B2 FOR THERAPY AND PROPHYLAXIS OF ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS), OR ARC BRISTOL-MYERS SQUIBB COMPANY 2004-10-12 US disclosed
US-20030181490-A1 HIV integrase inhibitors WALKER MICHAEL A (US) 2003-09-25 US disclosed
EP-1322599-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-07-02 EP disclosed
US-20030027847-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2003-02-06 US disclosed
WO-2001096283-A9 HIV INTEGRASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2002-10-17 WO disclosed
WO-2001096283-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043370-A1 HIV integrase inhibitors AKR1C3, CBR3, CBR1 HDAC6 2521/4885MEN1 4741/4885KMT2A 1208/4885
US-20030181490-A1 HIV integrase inhibitors CBR1, CCR5, CCR1 HDAC6 2328/4885MEN1 4837/4885KMT2A 1330/4885
US-20030027847-A1 HIV integrase inhibitors CBR1, CCR5, CCR1 HDAC6 2328/4885MEN1 4837/4885KMT2A 1330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.